Please upgrade your browser.
More than 2,000 investigators will present their latest research on topics in urology, including prostate, bladder and kidney cancer; benign prostatic hyperplasia (BPH, or enlarged prostate); and other genitourinary diseases and conditions.
"Our study suggests that patients with metastatic renal cell carcinoma who received sequential therapy with sorafenib first, followed by sunitinib at the time of sorafenib failure, had overall longer disease control..."
The NHS drugs watchdog NICE has in principle approved a kidney cancer drug which can increase survival by a year. Sunitinib is one of the first drugs to be approved under new guidance urging a more liberal approach to treatments which only marginally extend life.
Merck & Co. is not ruling out purchasing a major drugmaker as it looks "across the whole spectrum" of options, CEO Richard Clark said.
"These results were disappointing, given the trend towards prolonged survival seen in a Phase II study of axitinib in this extremely difficult-to-treat patient population,"
Swiss drugmaker Roche Holding reduced its acquisition offer for Genentech from $89 to $86.50 a share after negotiations with the biotech firm failed.
MDX-1203 contains an antibody that targets a protein called CD70, which is found in leukemia, lymphoma, renal cell carcinoma and other cancers.
Lorus Therapeutics Publishes Study Demonstrating LOR-2040 Improves Anticancer Effects of Interferon in Kidney Cancer
The article entitled "GTI-2040 Displays Cooperative Anti-Tumor Activity when Combined with Interferon alpha against Human Renal Carcinoma Xenografts" was published in the International Journal of Oncology (2009, Vol. 34: 33-42).
Securing rest of world IL-21 rights supports our strategy of seeking a global partner for this oncology asset, and were pleased to have accomplished this without near-term cash outlays, said Heather Franklin, Senior Vice President, Business Development. In the first half of this year, we plan to present Phase 2 results in renal cell carcinoma and metastatic melanoma.
Medicare, with little public debate, has expanded its coverage of drugs for cancer treatments not approved by the Food and Drug Administration.
|Powered by NeonCRM|